Conjugate Vaccine Market Report 2026

Conjugate Vaccine Market Overview

• Conjugate Vaccine market size has reached to $21.26 billion in 2025 • Expected to grow to $38.54 billion in 2030 at a compound annual growth rate (CAGR) of 12.8% • Growth Driver: Rising Infectious Diseases Is Anticipated To Fuel The Growth Of The Conjugate Vaccine Market • Market Trend: Industry Leader Embraces The Next-Generation 21-Valent Pneumococcal Conjugate vaccines-market" target="_blank">vaccines Advancements • North America was the largest region in 2025.

What Is Covered Under Conjugate Vaccine Market?

Conjugate vaccines, also known as immunogen conjugates, are advanced immune system modulators widely employed to develop protection against invading pathogens or make particular antibodies against the target molecule. The conjugation process enhances the immune response and allows for a more effective immune system recognition of the pathogen. The main types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines are vaccines that contain a single conjugated antigen, typically targeting a specific pathogen or strain, and are used to prevent infections caused by bacteria that have a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. They are developed with such bacterial and viral pathogens for the treatment of various diseases, including pneumococcal, influenza, meningococcal, and typhoid, for pediatric and adult patients used by hospitals, clinics, homecare settings, and others.

What Is The Conjugate Vaccine Market Growth Forecast?

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $38.54 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to rising demand for combination vaccines, expansion of adult vaccination programs, increased funding for vaccine r&d, growing focus on antimicrobial resistance, improving cold chain infrastructure. Major trends in the forecast period include expansion of pediatric immunization programs, rising adoption of multivalent conjugate vaccines, increasing focus on long-term immunogenicity, growth in public-private vaccine partnerships, advancements in carrier protein technologies.

Global Conjugate Vaccine Market Segmentation

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine 2) By Pathogen: Bacterial, Viral 3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid 4) By Patient: Pediatric, Adults 5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

What Is The Driver Of The Conjugate Vaccine Market?

The rising incidence of infectious diseases is expected to propel the growth of the conjugate vaccine market. Infectious diseases are disorders caused by pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi, which can be transmitted, directly or indirectly, from one person to another, from animals to humans, or through the environment. Conjugate vaccines play a crucial role in preventing infectious diseases caused by certain bacteria, especially in vulnerable populations such as infants and young children. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Additionally, the incidence rate climbed from 2.5 per 100,000 individuals in 2022 to 2.9 in 2023. Therefore, the rising incidence of infectious diseases is driving the growth of the conjugate vaccine industry.

Key Players In The Global Conjugate Vaccine Market

Major companies operating in the conjugate vaccine market are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Global Conjugate Vaccine Market Trends and Insights

Major companies operating in the conjugate vaccine market are focusing on developing next-generation conjugate vaccines to provide broader protection against multiple pneumococcal serotypes, thereby reducing disease burden in vulnerable populations. Next-generation conjugate vaccines attach bacterial polysaccharides to carrier proteins to boost immune response, particularly in infants and immunocompromised individuals, offering enhanced protection, prolonged immunity, and greater effectiveness compared to traditional vaccines. For instance, in August 2025, Pfizer Ltd., an India-based pharmaceutical company, launched its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., PCV20, for adults in India, thereby strengthening its conjugate vaccine portfolio by offering broader protection against pneumococcal disease and supporting improved public health outcomes.

What Are Latest Mergers And Acquisitions In The Conjugate Vaccine Market?

In December 2024, Sanofi, a France-based pharmaceutical company, expanded its collaboration with SK bioscience to advance the development of next-generation pneumococcal conjugate vaccines (PCV21). Through this partnership, Sanofi aims to accelerate the phase 3 clinical program for PCV21 and enhance its vaccine portfolio by leveraging SK bioscience’s expertise in vaccine development and manufacturing. SK bioscience is a South Korea-based conjugate vaccine manufacturer.

Regional Insights

North America was the largest region in the global conjugate vaccine market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Conjugate Vaccine Market?

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Conjugate Vaccine Market Report 2026?

The conjugate vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.